Tricuspid stenosis pathophysiology: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Tricuspid stenosis}} | {{Tricuspid stenosis}} | ||
{{CMG}} {{AE}} {{FB}} | {{CMG}} {{AE}} [[User:Mohammed Salih|Mohammed Salih, M.D.]] {{sali}} {{FB}} {{VKG}} | ||
==Overview== | ==Overview== | ||
Latest revision as of 04:46, 2 April 2020
|
Tricuspid stenosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tricuspid stenosis pathophysiology On the Web |
|
American Roentgen Ray Society Images of Tricuspid stenosis pathophysiology |
|
Risk calculators and risk factors for Tricuspid stenosis pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohammed Salih, M.D. Syed Musadiq Ali M.B.B.S.[2] Fatimo Biobaku M.B.B.S [3] Vamsikrishna Gunnam M.B.B.S [4]
Overview
Tricuspid stenosis (TS) is characterized by structural changes in the tricuspid valve. The pathophysiology of tricuspid valve depends on the underlying etiology. In rheumatic heart disease which is the most common cause of tricuspid stenosis, there is fibrous thickening of the valve leaflets and chordae tendineae with/without fusion of the commissures as a result of inflammation. The obstruction to right ventricular filling due to the stenotic tricuspid valve can result in systemic venous hypertension and congestion.
Pathophysiology
Pathogenesis
- The tricuspid disease is characterized by diffuse fibrous thickening of the leaflets and fusion of 2 or 3. [1][2][3][4][5]
- Leaflet thickening usually occurs in the absence of calcific deposits, and the anteroseptal commissure is most commonly involved.
- Incompletely developed leaflets, shortened or malformed chordae, a small annulus, or an abnormal number or size of papillary muscles may result in TS.
- The valves consist of an outer layer of valve endothelial cells (VECs) surrounding three layers of the extracellular matrix each with specialized function and interspersed with interstitial valve cells (VICs).
- Genetic or acquired/environmental causes that disrupt the normal organization and composition of the extracellular matrix and communication between VECs and VICs alter valve mechanics and interfere with the valve leaflet function, culminating in heart failure.
- As a result of valvular stenosis, there is a persistent diastolic pressure gradient between the right atrium and right ventricle. This gradient increases when blood flow across the tricuspid valve increases, as occurs with inspiration and exercise, and decreases when blood flow decreases, such as with expiration.[6]
- The primary result of TS is right atrial pressure elevation and consequent right-sided congestion.[7]
- During sinus rhythm, the right atrial "a" wave is increased and may approach the level of right ventricular systolic pressure.
- The resting cardiac output may be reduced and fails to increase with exercise.
- This may contribute to the only modestly elevated left atrial and pulmonary arterial pressures seen when mitral valve disease is also present.
- As a result, most patients with significant tricuspid stenosis have systemic venous congestion with jugular venous distension, ascites, and peripheral edema.
- The pathophysiology of tricuspid stenosis depends on the underlying etiology:[5]
Associated Conditions
- Rheumatic tricuspid stenosis:[9][10][5][11]
- Diffuse scarring and fibrosis of the valve leaflets from inflammation. Fusion of the commissures may or may not occur.
- Chordae tendineae may become thickened and shortened.
- As a result of the dense collagen and elastic fibers that make up leaflet tissue, the normal leaflet layers become significantly distorted.
- Carcinoid heart disease:
- Fibrous white plaques located on the valvular and mural endocardium are characteristic presentations of carcinoid valve lesions.[12][13][14]
- Valve leaflets become thick, rigid and smaller in area.
- Atrial and ventricular surfaces of the valve structure contain fibrous tissue proliferation.
- Congenital tricuspid stenosis:
- More common in infants
- Lesions may present in a number of different ways, either singularly or in any combination of the following:
- Incompletely developed leaflets
- Shortened or malformed chordae
- Small annuli
- Papillary muscles of abnormal size and number
- Infective endocarditis:
- Stenosis may develop as a result of large infected vegetations obstructing the opening of the tricuspid valve.[15]
- Other conditions may mimic tricuspid stenosis by the mechanical obstruction of flow through the tricuspid valve:
- Supravalvular obstruction from congenital diaphragms
- Intracardiac or extracardiac tumors
- Thrombosis or emboli
- Large endocarditis vegetations
- Other conditions that impair right-sided filling
References
- ↑ Shah PM, Raney AA (February 2008). "Tricuspid valve disease". Curr Probl Cardiol. 33 (2): 47–84. doi:10.1016/j.cpcardiol.2007.10.004. PMID 18222317.
- ↑ [+https://www.sciencedirect.com/science/article/pii/B9780124202191000124?via%3Dihub "Valvular Heart Disease - ScienceDirect"] Check
|url=value (help). - ↑ Farag M, Arif R, Sabashnikov A, Zeriouh M, Popov AF, Ruhparwar A, Schmack B, Dohmen PM, Szabó G, Karck M, Weymann A (February 2017). "Repair or Replacement for Isolated Tricuspid Valve Pathology? Insights from a Surgical Analysis on Long-Term Survival". Med. Sci. Monit. 23: 1017–1025. doi:10.12659/msm.900841. PMC 5338566. PMID 28236633.
- ↑ Salem A, Abdelgawad A, Elshemy A (August 2018). "Early and Midterm Outcomes of Rheumatic Mitral Valve Repair". Heart Surg Forum. 21 (5): E352–E358. doi:10.1532/hsf.1978. PMID 30311884. Vancouver style error: initials (help)
- ↑ 5.0 5.1 5.2 Waller BF, Howard J, Fess S (1995). "Pathology of tricuspid valve stenosis and pure tricuspid regurgitation--Part I." Clin Cardiol. 18 (2): 97–102. PMID 7720297.
- ↑ Nishimura RA, Carabello BA (May 2012). "Hemodynamics in the cardiac catheterization laboratory of the 21st century". Circulation. 125 (17): 2138–50. doi:10.1161/CIRCULATIONAHA.111.060319. PMID 22547754.
- ↑ Hinton RB, Lincoln J, Deutsch GH, Osinska H, Manning PB, Benson DW, Yutzey KE (June 2006). "Extracellular matrix remodeling and organization in developing and diseased aortic valves". Circ. Res. 98 (11): 1431–8. doi:10.1161/01.RES.0000224114.65109.4e. PMID 16645142.
- ↑ "Multimodal imaging of the tricuspid valve: normal appearance and pathological entities".
- ↑ Mathur A, Sharma N, Goyal P, Mittal P (August 2019). "Surgical Algorithm for Rheumatic Tricuspid Disease". Ann. Thorac. Surg. 108 (2): e129–e132. doi:10.1016/j.athoracsur.2019.02.009. PMID 30885854.
- ↑ Itzhaki Ben Zadok O, Sagie A, Vaturi M, Shapira Y, Schwartzenberg S, Kuznitz I, Shochat T, Bental T, Yedidya I, Aravot D, Kornowski R, Sharony R (February 2019). "Long-Term Outcomes After Mitral Valve Replacement and Tricuspid Annuloplasty in Rheumatic Patients". Ann. Thorac. Surg. 107 (2): 539–545. doi:10.1016/j.athoracsur.2018.09.012. PMID 30617023.
- ↑ Waller BF, Howard J, Fess S (March 1995). "Pathology of tricuspid valve stenosis and pure tricuspid regurgitation--Part II". Clin Cardiol. 18 (3): 167–74. doi:10.1002/clc.4960180312. PMID 7743689.
- ↑ Hayes AR, Davar J, Caplin ME (September 2018). "Carcinoid Heart Disease: A Review". Endocrinol. Metab. Clin. North Am. 47 (3): 671–682. doi:10.1016/j.ecl.2018.04.012. PMID 30098723.
- ↑ Hassan SA, Banchs J, Iliescu C, Dasari A, Lopez-Mattei J, Yusuf SW (October 2017). "Carcinoid heart disease". Heart. 103 (19): 1488–1495. doi:10.1136/heartjnl-2017-311261. PMID 28596302.
- ↑ Perry D, Hayek SS (November 2019). "Carcinoid Heart Disease: A Guide for Clinicians". Cardiol Clin. 37 (4): 497–503. doi:10.1016/j.ccl.2019.07.014. PMID 31587790.
- ↑ Aboukhoudir F, Boulet V, Rekik S, Pansieri M (November 2017). "[Lead-related infective endocarditis with massive vegetation causing severe functionnal tricuspid stenosis]". Ann Cardiol Angeiol (Paris) (in French). 66 (5): 326–329. doi:10.1016/j.ancard.2017.09.012. PMID 29050737.